A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.
Benjamin Musher(Baylor College of Medicine), Angelica Sara Ingrid Loskog(Uppsala University), Eric K. Rowinsky(The University of Texas at San Antonio), Salmaan Jawaid(Baylor College of Medicine), Brandon G. Smaglo(The University of Texas MD Anderson Cancer Center), Gustav Ullenhag(Uppsala University), Amanda Brisco(University of South Florida), Linda C. Sandin, Malcolm K. Brenner(Houston Methodist), Wasif M. Abidi(Baylor College of Medicine), Mohamed O. Othman(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), James Jing(Baylor College of Medicine), Justyna Leja-Jarblad, Kalpesh Patel(Baylor College of Medicine), Bambi Grilley(Baylor College of Medicine), Emma Eriksson(Uppsala University), Jessica Wenthe(Uppsala University)
Cited by 19
Related Papers
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
|Blood|2003|442
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
|Science|2011|440
Preoperative Treatment of Locally Advanced Rectal Cancer
|New England Journal of Medicine|2023|440